OnKure Therapeutics, Inc.
جودة البيانات: 83%
OKUR
NASDAQ
Manufacturing
Chemicals
KWD 4.67
▲
KWD 0.16
(3.55%)
6 months return
—
Momentum
Neutral
ROE
-82.32%
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-82.32%
أقل من متوسط القطاع (-54.47%)
ROIC-68.56%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio11.45
Interest Coverage-18.34
التقييم
PE (TTM|NTM)
-1.01 | -2.19
أعلى من متوسط القطاع (-1.50)
P/B Ratio0.91
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Negative free cash flow of -51.87 M
Price History
الاتجاهات المالية
السعر المستهدف للمحللين
5 محللين
Buy
+332.5%
upside to target
الحالي
KWD 4.67
Consensus Target
KWD 20.20
KWD 11.00
أدنى
KWD 30.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-2.19
ربحية السهم المستقبلية
-KWD 2.06
الإيرادات المقدّرة
666,670.0
مفاجآت الأرباح
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -KWD 0.74
·
Rev Est: 125,000.0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -KWD 1.19 | -KWD 1.14 | -KWD 1.09 | -KWD 0.99 | — | — |
| Estimate | -KWD 1.38 | -KWD 1.25 | -KWD 1.20 | -KWD 1.15 | -KWD 0.74 | -KWD 0.65 |
| المفاجأة | +13.77% | +8.65% | +9.02% | +14.06% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -82.32% · Net Margin: N/A
Profitability
ROE: -82.32% · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | -59.52 M |
| ROE | -82.32% | ROA | -74.91% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -51.87 M |
| ROIC | -68.56% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 11.45
Safety
D/E: N/A · Current: 11.45| Debt / Equity | N/A | Current Ratio | 11.45 |
| Interest Coverage | -18.34 | Asset Turnover | N/A |
| Working Capital | 65.28 M | Tangible Book Value | 66.43 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -1.01 · EV/EBITDA: N/A
Valuation
P/E: -1.01 · EV/EBITDA: N/A| P/E Ratio | -1.01 | Forward P/E | -2.19 |
| P/B Ratio | 0.91 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 90.35 | Fwd Earnings Yield | N/A |
| FCF Yield | -86.12% | ||
| Market Cap | 60.23 M | Enterprise Value | -10.10 M |
Per Share
EPS: -4.40 · FCF/Share: -3.79
Per Share
EPS: -4.40 · FCF/Share: -3.79| EPS (Diluted TTM) | -4.40 | Revenue / Share | N/A |
| FCF / Share | -3.79 | OCF / Share | -3.79 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 87.16% · CapEx/Rev: N/A
Efficiency
FCF Conv: 87.16% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 87.16% |
| SBC-Adj. FCF | -61.31 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 0.0 | — | — | — |
| Net Income | -59.52 M | -52.67 M | -77.39 M | -51.96 M | -39.77 M |
| EPS (Diluted) | -4.40 | -15.28 | -2.52 | -2.12 | -2.19 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -62.95 M | -54.39 M | -83.05 M | -53.85 M | -39.82 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 48.26 M | 43.80 M | 56.61 M | 37.71 M | 28.17 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 447,000.0 | 459,000.0 | 170,000.0 | 88,000.0 | 50,000.0 |
| Interest Expense | 3.43 M | 1.71 M | — | — | — |
| Income Tax | 0.0 | — | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 62.12 M | 114.91 M | 107.44 M | 108.18 M | 154.02 M |
| Total Liabilities | 5.93 M | 11.08 M | 18.83 M | 8.21 M | 6.81 M |
| Shareholders' Equity | 56.18 M | 103.83 M | 88.61 M | 99.97 M | 147.21 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 59.05 M | 110.76 M | 27.63 M | 19.93 M | 124.66 M |
| Current Assets | 60.84 M | 113.00 M | 106.62 M | 106.35 M | 153.73 M |
| Current Liabilities | 5.92 M | 10.53 M | 18.18 M | 7.12 M | 6.20 M |
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير)
مقارنة بشركات مشابهة في Manufacturing
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير) مقارنة بشركات مشابهة في Manufacturing| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.0 | -1.5 |
| P/B | 0.9 | 1.6 |
| ROE % | -82.3 | -54.5 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.9 |
| D/E | — | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"OKUR","listing_kind":"stock","pathname":"/stocks/okur","exchange":"NASDAQ","country":"US"}}